This interview will focus on the current treatment landscape and the prescribing patterns of Lexicon's dual SGLT1 and SGLT2 inhibitor Inpefa (sotagliflozin) in patients with heart failure
This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
2025 Q1 #2 Speaking with a Cardiologist who has experience treating heart failure patients to discuss the standard of care and the use of Inpefa (sotagliflozin).
Ticker(s): LXRXWho's the expert?
Institution: Premier Cardiovascular Institute
- Board certified in Internal Medicine, Cardiovascular Disease, Echocardiography, Nuclear Cardiology, and Interventional Cardiology.
- treats 3-4 patients per month with ATTR-CM and manages roughly 40 patients with Hypertrophic Cardiomyopathy.
- familiar with the results from the APOLLO-B Phase 3 Study of Patisiran
- familiar with Mavacamten and overall landscape of cardiovascular drugs.
Interview Goal
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
